CRISPR Therapeutics (CRSP) Guggenheim Securities Inaugural Healthcare Innovation Conference summary

Pipeline overview and innovation

• Achieved first global approval for a CRISPR-based medicine, CASGEVY, targeting sickle cell and thalassemia.

• Pipeline spans ex vivo and in vivo approaches, including allogeneic CAR T therapies and direct liver editing for cardiovascular targets like LP(a) and ANGPTL3.

• Regenerative medicine efforts focus on type 1 diabetes and solid tumors with advanced CAR T constructs.

CASGEVY launch and commercialization

• Vertex leads global commercialization, with exponential growth in patient cell collections and ATC activations.

• Market opportunity is larger than anticipated, especially in Europe and the Middle East.

• Targeted conditioning regimens are in development to expand the eligible patient pool, with profit-sharing agreements in place.

• In vivo solutions for sickle cell and thalassemia could shift profit sharing to a 50/50 structure in 8–10 years.

Allogeneic CAR T (CTX112) and autoimmune applications

• CTX112 shows a strong safety and efficacy profile, with high CR rates and potential to outperform autologous CAR T therapies.

• Allogeneic CAR T aims to reach community settings, addressing a broader patient population.

• Safety profile is favorable, with lower rates of severe ICANS compared to autologous CAR T.

• Multiple gene edits are possible, with current constructs balancing potency and safety.

• Allogeneic CAR T is positioned as best-in-class for autoimmune diseases, offering one-time treatment and easier patient management.